Alcohol Septal Ablation: An Option on the Rise in Hypertrophic Obstructive Cardiomyopathy

Area of Science:

• Cardiology
• Interventional Cardiology
• Cardiac Surgery

Background:

• Hypertrophic cardiomyopathy (HCM) can lead to left ventricle outflow tract (LVOT) obstruction, causing significant symptoms.
• Pharmacological therapy is the initial treatment, but many patients require invasive interventions for symptom management.

Purpose of the Study:

• To compare the efficacy and safety of septal reduction therapies, specifically alcohol septal ablation (ASA) and septal myectomy (SM), in managing obstructive HCM.
• To evaluate the long-term outcomes, including mortality and complication rates, associated with both ASA and SM.

Main Methods:

• Alcohol septal ablation (ASA) involves targeted infusion of alcohol into a septal artery to induce infarction and reduce LVOT obstruction.
• Septal myectomy (SM) is a surgical procedure to remove thickened septal muscle obstructing the LVOT.
• Current guidelines indicate similar levels of recommendation for both ASA and SM, with ASA often reserved for elderly patients or those with comorbidities.

Main Results:

• Recent data indicates no significant differences in short- and long-term all-cause mortality, cardiovascular mortality, or sudden cardiac death between ASA and SM.
• Complete atrio-ventricular block, necessitating a permanent pacemaker, remains the most frequent complication despite technical advancements in ASA.

Conclusions:

• Both ASA and SM are effective septal reduction therapies for obstructive HCM, demonstrating comparable long-term survival.
• While effective, complete atrio-ventricular block is a significant complication of ASA, highlighting the need for experienced centers.
• Septal reduction therapies should be performed in specialized centers with comprehensive cardiac programs to optimize patient outcomes.